ArticleFrontiers in bioscience (Elite edition)2012
Pathogenesis of Chagas disease: time to move on.
Article in Frontiers in bioscience (Elite edition), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 49 citations in OpenAlex.
- Endothelial transmigration by Trypanosoma cruzi.PloS one · 2013Trial
- Gasdermins in Innate Host Defense AgainstFrontiers in immunology · 2022Review
- CXCL9 and CXCL10 display an age-dependent profile in Chagas patients: a cohort study of aging in Bambui, Brazil.Infectious diseases of poverty · 2020Article
- Understanding CD8Trends in parasitology · 2019Review
- Observational
- Pathology and Pathogenesis of Chagas Heart Disease.Annual review of pathology · 2019Review
- PARP1 depletion improves mitochondrial and heart function in Chagas disease: Effects on POLG dependent mtDNA maintenance.PLoS pathogens · 2018Article
- Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.Infection and immunity · 2018Article
- Pathogenesis of Chronic Chagas Disease: Macrophages, Mitochondria, and Oxidative Stress.Current clinical microbiology reports · 2018Article
- Pentose Phosphate Shunt Modulates Reactive Oxygen Species and Nitric Oxide Production ControllingFrontiers in immunology · 2018Article
- New Insights into the Immunobiology of Mononuclear Phagocytic Cells and Their Relevance to the Pathogenesis of Cardiovascular Diseases.Frontiers in immunology · 2017Review
- Sanitation for all: the global opportunity to increase transgenerational health gains and better understand the link between NCDs and NTDs, a scoping review.Tropical diseases, travel medicine and vaccines · 2017Article
- Chemotherapeutic efficacy of phosphodiesterase inhibitors in chagasic cardiomyopathy.JACC. Basic to translational science · 2016Article
- Pupillary Light Reflexes are Associated with Autonomic Dysfunction in Bolivian Diabetics But Not Chagas Disease Patients.The American journal of tropical medicine and hygiene · 2016Article
- Phenotypic Features of Circulating Leukocytes from Non-human Primates Naturally Infected with Trypanosoma cruzi Resemble the Major Immunological Findings Observed in Human Chagas Disease.PLoS neglected tropical diseases · 2016Article
- Developments in the management of Chagas cardiomyopathy.Expert review of cardiovascular therapy · 2015Review
- Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead.The American journal of pathology · 2015Review
- A Two-Component DNA-Prime/Protein-Boost Vaccination Strategy for Eliciting Long-Term, Protective T Cell Immunity against Trypanosoma cruzi.PLoS pathogens · 2015Article
- Deep sequencing of the Trypanosoma cruzi GP63 surface proteases reveals diversity and diversifying selection among chronic and congenital Chagas disease patients.PLoS neglected tropical diseases · 2015Article
- Amblyomma americanum tick calreticulin binds C1q but does not inhibit activation of the classical complement cascade.Ticks and tick-borne diseases · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
Abstract
Trypanosoma cruzi is the etiologic agent of Chagas disease. The contributions of parasite and immune system for disease pathogenesis remain unresolved and controversial. The possibility that Chagas disease was an autoimmune progression triggered by T. cruzi infection led some to question the benefit of treating chronically T. cruzi-infected persons with drugs. Furthermore, it provided the rationale for not investing in research aimed at a vaccine which might carry a risk of inducing autoimmunity or exacerbating inflammation. This viewpoint was adopted by cash-strapped health systems in the developing economies where the disease is endemic and has been repeatedly challenged by researchers and clinicians in recent years and there is now a considerable body of evidence and broad consensus that parasite persistence is requisite for pathogenesis and that antiparasitic immunity can be protective against T. cruzi pathogenesis without eliciting autoimmune pathology. Thus, treatment of chronically infected patients is likely to yield positive outcomes and efforts to understand immunity and vaccine development should be recognized as a priority area of research for Chagas disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.